Background
Methods
Design
Setting & participants
Study process and interventions
Outcomes
Statistics
Results
Variables n = 36 | Group 1 n = 18 | Group 2 n = 18 | P-Value | |
---|---|---|---|---|
Mean ± SD | Mean ± SD | |||
Age (Years) | 47.22 ± 14.17 | 53.89 ± 14.11 | 0.17 | |
Duration of Known Hepatitis C (Years) | 4.61 ± 3.84 | 3.55 ± 1.92 | 0.31 | |
Duration of Dialysis (Years) | 4.23 ± 2.63 | 5.33 ± 2.79 | 0.23 | |
HCV RNA PCR (log 10 IU/ml) | 5.88 ± 6.0 | 6.16 ± 6.58 | 0.46 | |
Gender | Male | N = 11 | N = 11 | ___ |
Female | N = 7 | N = 7 | ||
Genotype 1 Patients | N = 06 | N = 06 | ___ | |
Genotype 2 Patients | N = 00 | N = 01 | ___ | |
Genotype 3 Patients | N = 12 | N = 11 | ___ | |
Cirrhosis | N = 04 | N = 06 | ___ | |
Treatment Experienced | N = 03 | N = 02 | ___ | |
Treatment Withdrawal | N = 03 | N = 01 | ___ | |
Aspartate Aminotransferase (U/L) | 57.06 ± 48.71 | 34.5 ± 25.27 | 0.09 | |
Alanine Aminotransferase (U/L) | 50.89 ± 44.08 | 40.50 ± 34.86 | 0.44 | |
Hemoglobin (g/dl) | 10.53 ± 1.61 | 11.51 ± 1.15 | 0.04 | |
White Blood Cells × 103/mm3 | 6.33 ± 1.93 | 6.44 ± 1.91 | 0.87 | |
Platelets ×103/mm3 | 163.27 ± 65.34 | 175.44 ± 40.11 | 0.51 | |
Independent t-test was used to assess the significance |
Variables | Group* | Mean ± SDVsMean±SD | P-Value | |
---|---|---|---|---|
Aspartate Aminotransferase U/L | Baseline VS 24th Week | 1 | 57.06 ± 48.71Vs 20.17 ± 7.70 | 0.08 |
2 | 34.5 ± 25.27 Vs 21.61 ± 8.23 | 0.07 | ||
Alanine Aminotransferase U/L | Baseline VS 24th Week | 1 | 50.89 ± 44.08 Vs 20.78 ± 10.81 | 0.02 |
2 | 40.5 ± 34.85 Vs 22.28 ± 11.92 | 0.06 | ||
Hemoglobin g/dl | Baseline VS 24th Week | 1 | 10.53 ± 1.61 Vs 10.31 ± 1.69 | 0.70 |
2 | 11.51 ± 1.14 Vs 10.02 ± 1.712 | 0.002 | ||
White Blood Cells ×103/mm3 | Baseline VS 24th Week | 1 | 6.33 ± 1.94 Vs 5.78 ± 1.16 | 0.37 |
2 | 6.44 ± 1.91 Vs 6.61 ± 1.64 | 0.78 | ||
Platelets ×103/mm3 | Baseline VS 24th Week | 1 | 163.27 ± 65.90Vs 172.94 ± 62.74 | 0.61 |
2 | 175.44 ± 40.11 Vs 184.89 ± 53.82 | 0.58 | ||
Paired t-test was used to assess the significance |
Viral load detectable | ||||
---|---|---|---|---|
Group 1(n = 18) | Group 2 (n = 18) | |||
No | Yes | No | Yes | |
N (%) | N (%) | N (%) | N (%) | |
4th Week (RVR) | 14 (77.7) | 1 (6.6) | 15 (83.3) | 2 (11.1) |
8th Week | 15 (83.3) | (0) | 17 (94.4) | 0 (0) |
12th Week (ETR) | 15 (83.3) | (0) | 17 (94.4) | 0 (0) |
24th Week (SVR) | 15 (83.3) | (0) | 14 (77.7) | 3 (16.6) |
Viral load detectable | ||||
---|---|---|---|---|
Group 1(n = 15) | Group 2 (n = 17) | |||
No | Yes | No | Yes | |
N (%) | N (%) | N (%) | N (%) | |
4th Week (RVR) | 14 (93.4) | 1 (6.6) | 15 (88.3) | 2 (11.7) |
8th Week | 15 (100) | 0 (0) | 17 (100) | 0 (0) |
12th Week (ETR) | 15 (100) | 0 (0) | 17 (100) | 0 (0) |
24th Week (SVR) | 15 (100) | 0 (0) | 14 (82.3) | 3 (17.7) |
Gender | Cirrhosis | Previous Treatment | Baseline PCR (log 10 IU/ml) | ETR | SVR12 PCR (log 10 IU/ml) | Genotype |
---|---|---|---|---|---|---|
Male | No | Yes | 5.86 | Not Detected | 5.51 | 1 |
Female | No | No | 5.60 | Not Detected | 4.11 | 1 |
Male | No | Yes | 5.86 | Not Detected | 5.50 | 1 |